ClinicalTrials.gg
RecruitingNCT07384975MainsailUpdated Jul 22, 2026

A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa

A Phase 2 interventional study of NAV-240 and Placebo to match NAV-240 in Hidradenitis Suppurativa (HS), sponsored by Navigator Medicines, Inc.. Recruiting at 41 sites in 8 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by Navigator Medicines, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 161 studies in Hidradenitis Suppurativa with a site in United States — 38 open to participants now, 55 under way, 12 of them phase 3. Hidradenitis Suppurativa · United States.

Planned enrollment
48th of 139
150 · median 45
Started
2026
with 16 others
Phase 2
61 of 161
11 open now
Primary completion
2027-09
later than 29 of 54 live
Registered
150th of 161
by date

Among the 161 studies in Hidradenitis Suppurativa with a site in United States, this one is the 48th largest by planned enrollment of the 139 interventional ones that give a count, is one of 17 that started in 2026, is one of 61 in phase 2, reaches primary completion later than 29 of the 54 other live ones, and was the 150th registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

38 of the 161 studies in Hidradenitis Suppurativa with a site in United States are open now. Recruiting first, the newest first:

32 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 161 studies in Hidradenitis Suppurativa with a site in United States, or all of them as a file.
02

Study summary

The main objective of this study is to determine if NAV-240 works more effectively than a dummy treatment (placebo) for participants with moderate-to-severe HS. The main endpoint of this study is the percentage of participants achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 75 at Week 16, meaning at least a 75% reduction in inflamed skin bumps (abscess and inflammatory nodule (AN) count) with no increase in number of abscesses or draining tunnels (channels under the skin that leak fluid or pus) compared to the baseline (start of the study).

Participants will:

  • Receive NAV-240 dose 1, NAV-240 dose 2 or placebo as a drip into the veins (intravenous infusion).
  • Visit the clinic up to 9 times for checkups and tests over 22 weeks.
  • Complete a daily diary about their skin pain.
03

Conditions studied

  • Hidradenitis Suppurativa (HS)

Keywords

  • NAV-240
  • HS
  • Hidradenitis Suppurativa
  • Phase 2
  • Moderate-to-Severe HS
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of stable HS for ≥ 2 months
  • Abscesses and Inflammatory Nodules (lesion) count ≥ 5
  • Inflammatory HS lesions in at least 2 different body regions, one of which must be Hurley Stage II or III
  • Inadequate response to at least one course of antibiotics
  • Topical antiseptics/washes are not required but allowed. If in use, the participant must agree to use one single product consistently through Week 16.
  • Use of oral antibiotics is allowed during the study under the following conditions: the dose and regimen must remain stable until Week 16. Allowed oral antibiotics include doxycycline, minocycline, or tetracycline.
  • Female participants of must have a negative pregnancy test
  • Participants of must use a highly effective method of

Exclusion criteria

Exclusion Criteria:

  • > 20 draining tunnel count
  • Active skin disease (bacterial, fungal, viral infection) that, in the opinion of the Investigator, could interfere with assessment of HS or requires treatment with antibiotic(s) also used to treat HS.
  • Has had major surgery, including HS surgery, within 12 weeks prior to Day 1
  • History of alcohol or drug abuse within the past 2 years.
  • A positive urine drug screen at Screening
  • History or evidence of (HIV), or virus (HCV), or a positive test at Screening
  • History or current diagnosis of active or latent pulmonary or extrapulmonary TB infection or a positive test at Screening
  • History of moderate to severe heart failure or recent (within past 6 months) cerebrovascular accident, myocardial infarction, or coronary stenting.
  • Any history of (including lymphoma and leukemia) other than a successfully treated and considered cured non- cutaneous squamous cell carcinoma, basal cell carcinoma or localized carcinoma in situ
  • History of immune deficiency
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    NAV-240 Dose 1

    NAV-240 Dose 1

    Drug: NAV-240

  • Experimental
    NAV-240 Dose 2

    NAV-240 Dose 2

    Drug: NAV-240

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo to match NAV-240

Interventions

  • NAV-240 for Intravenous Infusion

  • DrugPlacebo to match NAV-240

    Placebo to match NAV-240 for Intravenous Infusion

06

What researchers measure

Primary outcomes

  1. Proportion of participants achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 75

    HiSCR75 is defined as at least a 75% reduction in total abscess and inflammatory nodule count (AN count) with no increase in abscess count and no increase in draining tunnel count relative to baseline.

    Time frame: Baseline to Week 16

Secondary outcomes

  1. Proportion of participants achieving skin pain numeric rating scale (NRS) 30 response

    NRS30 is defined as a ≥ 30% reduction and at least a 2-unit reduction from baseline in skin pain on the NRS, for participants with a baseline skin pain NRS ≥ 3, based on the weekly average of the worst skin pain in a 24-hour recall period (maximal daily pain). The skin pain NRS is a single-item measure designed to capture information on self-reported skin pain severity by rating "the worst level of skin pain in the past 24 hours" as a number on a numerical rating scale from 0 (no pain) to 10 (worst pain imaginable).

    Time frame: Baseline to Week 16

  2. Proportion of participants achieving HiSCR50

    HiSCR50 is defined as at least a 50% reduction in total AN count with no increase in abscess count and no increase in draining tunnel count relative to baseline.

    Time frame: Baseline to Week 16

  3. Proportion of participants achieving a Dermatology Life Quality Index (DLQI) improvement (reduction) of ≥ 4 points among participants with DLQI ≥ 4 at baseline

    The DLQI is a simple validated 10-item, dermatology-specific, quality-of-life (QoL) questionnaire. Each item in the questionnaire can receive an impairment degree on a 4-point-scale (0 - not at all, 3 - very much), and the higher the score, the greater the impairment of QoL.

    Time frame: Baseline to Week 16

  4. Proportion of participants with HS flare

    Time frame: Baseline to Week 16

  5. Change in the International Hidradenitis Suppurativa Severity Score System (IHS4) scores

    The IHS4 score is arrived at by the number of nodules (multiplied by 1) plus the number of abscesses (multiplied by 2) plus the number of draining tunnels (multiplied by 4). A total score of 3 or less is a mild disease, 4-10 signifies moderate disease and 11 or higher signifies severe disease.

    Time frame: Baseline to Week 16

  6. Change from baseline in AN count

    Time frame: Baseline to Week 16

  7. Change from baseline in the number of draining tunnels

    Time frame: Baseline to Week 16

Other outcomes

  1. Incidence of TEAEs, SAEs and adverse events of special interest (AESIs)

    Time frame: Baseline to Week 16

07

Study locations

40 of 41 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Sep 2027, 20 months after the start.

Of 44 industry-sponsored phase 2 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's planned 20 months is above that.

Counting every sponsor, half of 54 studies reached it within 15 months; a quarter within 11 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2026
First posted
Feb 3, 2026
StartActual
Jan 5, 2026
Primary completionEst.
Sep 2027
CompletionEst.
Oct 2027
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07384975
Lead sponsor
Navigator Medicines, Inc.
Responsible party
Sponsor
First posted
Feb 3, 2026
Start date
Jan 5, 2026
Primary completion
Sep 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Jul 22, 2026

Study contacts

Associate Director, Clinical Operations
Contact
info@navigatormeds.com
+1 415 251 7753
Vice President, Development Operations
Contact
Lara Pupim, MD, MSCI
study director · Navigator Medicines, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NAV-240

Start the discussion